

MULTIPLE SCLEROSIS REFERRAL FORM

NPI #: 1801060298
BIOMATRIX TEL: 855-359-9679 FAX: 610-545-6030

Patient Name _____ SS# _____ DOB _____ Male Female
 Street Address _____ Apt# _____ City _____ State _____ Zip _____
 Daytime Tel _____ Cell _____ Email _____ Height _____ Weight _____ BSA _____
 Ship to Patient at Home Work OR Patient will pick up at Physician Office Local Pharmacy Phone _____
 Allergies _____ Comorbidities _____
 Current Medications (if necessary, please fax a complete list) _____

PRACTICE NAME	ADDRESS	PHONE	PRIMARY CONTACT
_____	_____	_____	_____
PRESCRIBER INFORMATION (PLEASE INCLUDE PHYSICIAN NAME AND NPI#)			
<input type="checkbox"/> _____ # _____	<input type="checkbox"/> _____ # _____	<input type="checkbox"/> _____ # _____	<input type="checkbox"/> _____ # _____
<input type="checkbox"/> _____ # _____	<input type="checkbox"/> _____ # _____	<input type="checkbox"/> _____ # _____	<input type="checkbox"/> _____ # _____
<input type="checkbox"/> _____ # _____	<input type="checkbox"/> _____ # _____	<input type="checkbox"/> _____ # _____	<input type="checkbox"/> _____ # _____

Insured's Name _____ Relation to Patient _____
 Eligible for Medicare Yes No If yes, Medicare# _____ Prescription Card Yes No If Yes, Carrier _____
 Tel _____ Fax _____ Policy/Group# _____
 Bin# _____ Pcn# _____ RXID# _____ RX Group# _____

ICD-10 Code **G35** Multiple Sclerosis OR Other _____ Patient Weight _____
 Relapse Remitting Primary Progressive Secondary Progressive
 Patient currently on therapy? Yes No Date of next blood work _____
 Comments _____

PRESCRIPTION

PLEASE ATTACH COPIES OF PATIENT'S INSURANCE CARDS

<input type="checkbox"/> AMPRYRA (dalfampridine) 10 mg extended release tablet SIG: _____ mg PO twice daily QTY: _____ Refills: _____	<input type="checkbox"/> LEMTRADA (alemtuzumab) 12 mg/1.2 mL(10 mg/mL) vial <input type="checkbox"/> First course: 12 mg/day on 5 consecutive days QTY: 5 vials <input type="checkbox"/> Second course: 12 mg/day on 3 consecutive days 12 months after first treatment course. QTY: 3 vials <input type="checkbox"/> Maintenance course: 12 mg/day on 3 consecutive days 12 months after the last dose of the prior treatment course. QTY: 3 vials <input type="checkbox"/> Other _____ QTY: _____
<input type="checkbox"/> AUBAGIO (teriflunomide) <input type="checkbox"/> SIG: 7 mg: 1 tablet by mouth daily with or without food <input type="checkbox"/> SIG: 14 mg: 1 tablet by mouth daily with or without food QTY: _____ Refills: _____	<input type="checkbox"/> OCREVUS (ocrelizumab) 300 mg/10 mL vial <input type="checkbox"/> Loading Dose: Infuse 300 mg IV on Day 1 followed by 300 mg IV 2 weeks later QTY: 2 Vials Refills: 0 <input type="checkbox"/> Maintenance Dose (beginning 6 months after first 300 mg dose) Infuse 600 mg IV once every 6 months QTY: 2 vials Refills: _____
<input type="checkbox"/> AVONEX (interferon beta-1a) 30mcg Dispense: <input type="checkbox"/> Pen <input type="checkbox"/> PFS <input type="checkbox"/> SIG: Inject 30 mcg IM once weekly <input type="checkbox"/> SIG: Other _____ QTY: 1 pack = 4 week supply Refills: _____	<input type="checkbox"/> REBIF (interferon beta-1a) <input type="checkbox"/> REBIF 22mcg Prescribed Dose <input type="checkbox"/> REBIF TITRATION PACK SIG: Inject 4.4 mcg (0.1 mL) subcutaneously TIW (at least 48hrs apart) weeks 1 & 2. Then inject 11 mcg (0.25 mL) TIW weeks 3 & 4 QTY: 1 pack Refills: 0
<input type="checkbox"/> BETASERON (interferon beta-1b) 0.3 mg vial <input type="checkbox"/> EXTAVIA VIALS (interferon beta-1b) 0.3 mg vial Starting Dose: <input type="checkbox"/> Inject 0.0625 mg (0.25 mL) subcutaneously every other day for weeks 1 & 2 QTY: 1 pack Refills: 0 <input type="checkbox"/> Inject 0.125 (0.5 mL) subcutaneously every other day for weeks 3 & 4 QTY: 1 pack Refills: 0 <input type="checkbox"/> Inject 0.1875 (0.75 mL) subcutaneously every other day for weeks 5 & 6 QTY: 1 pack Refills: 0	<input type="checkbox"/> REBIF 22mcg Prescribed Dose <input type="checkbox"/> REBIF 44mcg Prescribed Dose <input type="checkbox"/> REBIF TITRATION PACK SIG: Inject 8.8 mcg subcutaneously TIW (at least 48hrs apart) weeks 1 & 2. Then inject 22 mcg TIW weeks 3 & 4 QTY: 1 pack Refills: 0
Maintenance Dose: <input type="checkbox"/> Inject 0.25 mg (1 mL) subcutaneously every other day <input type="checkbox"/> Other _____ QTY: 1 pack = 4 week supply Refills: _____	<input type="checkbox"/> REBIF 44mcg Prescribed Dose <input type="checkbox"/> REBIF TITRATION PACK SIG: Inject 8.8 mcg subcutaneously TIW (at least 48hrs apart) weeks 1 & 2. Then inject 22 mcg TIW weeks 3 & 4 QTY: 1 pack Refills: 0
<input type="checkbox"/> COPAXONE (glatiramer acetate) <input type="checkbox"/> GLATOPA (glatiramer acetate) <input type="checkbox"/> GLATIRAMER ACETATE Dose: <input type="checkbox"/> 20 mg PFS <input type="checkbox"/> 40 mg PFS <input type="checkbox"/> SIG: Inject 20 mg subcutaneously once daily QTY: 30 Refills: _____ <input type="checkbox"/> SIG: Inject 40 mg subcutaneously three times a week QTY: 12 Refills: _____ <input type="checkbox"/> SIG: Other _____ QTY: _____ Refills: _____	<input type="checkbox"/> REBIF (interferon beta-1a) 44mcg/0.5ml Dispense: <input type="checkbox"/> Pen <input type="checkbox"/> PFS SIG: 44 mcg (0.5ml) subcutaneously TIW (at least 48hrs apart) starting week 5 and thereafter QTY: 1 pack = 4 week supply Refills: _____
<input type="checkbox"/> GILENYA (fingolimod) 0.5 mg (first dose must be taken at the doctor's office) SIG: >40kg: 1 capsule by mouth daily QTY: _____ Refills: _____	<input type="checkbox"/> TYSABRI (natalizumab) 300 mg vial SIG: Infuse 300mg IV over 1 hour every 4 weeks QTY: 1 vial Refills: _____
<input type="checkbox"/> OTHER _____ SIG: _____ QTY: _____ Refills: _____	

By signing this form and utilizing our services, you are authorizing BioMatrix Specialty Pharmacy, its subsidiaries and their employees to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies where allowed by law or contract.

Prescriber's Signature _____ *(Signature required. NO STAMPS)* **AND** Hand write: brand medically necessary, if needed **Date** _____

Prescriber's Email _____

IMPORTANT NOTICE: This message may contain privileged and confidential information and is intended only for the individual named. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document by mistake, then destroy this document. Please direct all verification or notification to BioMatrix Specialty Pharmacy or any of its subsidiaries using the contact information provided on this cover sheet. RF031-SP_v4 03/20